| Incyte Gets FDA Approval for Zynyz in New Cancer Indication |
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer. |
zacks.com |
2025-05-16 15:55:11 |
Czytaj oryginał (ang.) |
| Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States. |
businesswire.com |
2025-05-15 18:30:00 |
Czytaj oryginał (ang.) |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-05-07 20:30:00 |
Czytaj oryginał (ang.) |
| Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript |
Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research and Development Christiana Stamoulis - Executive Vice President and Chief Financial Officer Matteo Trotta - EVP, Head of U.S. Dermatology Mohamed Issa - EVP, Head of U.S. Oncology Steven Stein - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim David Lebowitz - Citi Andrew Barrons - Leerink Partners Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Chase Marc Frahm - TD Cowen Vikram Purohit - Morgan Stanley Ash Verma - UBS James Shin - Deutsche Bank Salim Syed - Mizuho Securities Gavin Clark-Gartner - Evercore ISI Jay Olson - Oppenheimer Operator Greetings, and welcome to the Incyte's First Quarter 2025 Earnings Conference and Webcast. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-04-29 16:53:05 |
Czytaj oryginał (ang.) |
| INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales |
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales. |
zacks.com |
2025-04-29 16:05:34 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings |
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-29 14:35:57 |
Czytaj oryginał (ang.) |
| Incyte (INCY) Q1 Earnings and Revenues Top Estimates |
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago. |
zacks.com |
2025-04-29 13:15:39 |
Czytaj oryginał (ang.) |
| Incyte raises 2025 sales forecast for blood cancer drug after solid quarter |
Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results. |
reuters.com |
2025-04-29 13:03:17 |
Czytaj oryginał (ang.) |
| Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs. |
businesswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025. |
businesswire.com |
2025-04-25 12:00:00 |
Czytaj oryginał (ang.) |
| Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know |
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi. |
zacks.com |
2025-04-23 12:50:40 |
Czytaj oryginał (ang.) |
| Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth |
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-22 15:06:02 |
Czytaj oryginał (ang.) |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-04-07 20:30:00 |
Czytaj oryginał (ang.) |
| Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico |
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| Why Incyte Stock Was Tanking This Week |
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open. |
fool.com |
2025-03-21 13:56:19 |
Czytaj oryginał (ang.) |
| INCY Stock Down on Disappointing Skin Disease Study Data |
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations. |
zacks.com |
2025-03-18 18:00:30 |
Czytaj oryginał (ang.) |
| Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib |
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing. |
seekingalpha.com |
2025-03-18 17:39:57 |
Czytaj oryginał (ang.) |
| Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results |
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial. |
investopedia.com |
2025-03-17 14:30:56 |
Czytaj oryginał (ang.) |
| Incyte Is Today's Worst S&P 500 Stock. Here's Why. |
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough. |
barrons.com |
2025-03-17 13:21:00 |
Czytaj oryginał (ang.) |
| Incyte Stock Eyes Worst Day Since 2018 After Trial Results |
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants. |
schaeffersresearch.com |
2025-03-17 12:44:46 |
Czytaj oryginał (ang.) |
| Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration |
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration. |
businesswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Incyte to Present at Upcoming Investor Conferences |
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST) Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceu. |
businesswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Reevaluating Incyte Corporation After Earnings (Technical Analysis) |
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below its 30-week EMA, with short-term bearish momentum but long-term bullish momentum, making it a cautious buy. Volume analysis shows neutral institutional activity, and relative strength indicates INCY is trading on par with the S&P 500 since May 2024. |
seekingalpha.com |
2025-02-12 10:30:00 |
Czytaj oryginał (ang.) |
| Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025 |
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline with four product launches in 2025 and potential $1B incremental revenue by 2029 bodes well for continued growth. The company has a strong track record of revenue growth and a robust pipeline targeting over 10 high-impact product launches by 2030. |
seekingalpha.com |
2025-02-11 09:30:00 |
Czytaj oryginał (ang.) |
| INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales |
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales. |
zacks.com |
2025-02-10 13:56:11 |
Czytaj oryginał (ang.) |
| Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript |
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - RBC Capital Markets Jay Olson - Oppenheimer Matt Phipps - William Blair Andrew Berens - Leerink Partners Andy Chen - Wolfe Research Salim Sayed - Mizuho Evan Seigerman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. |
seekingalpha.com |
2025-02-10 13:52:24 |
Czytaj oryginał (ang.) |
| Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-10 12:31:08 |
Czytaj oryginał (ang.) |
| Incyte (INCY) Q4 Earnings Miss Estimates |
Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago. |
zacks.com |
2025-02-10 11:15:23 |
Czytaj oryginał (ang.) |
| Incyte reports quarterly sales above estimates on strong demand for key drugs |
Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura. |
reuters.com |
2025-02-10 10:38:29 |
Czytaj oryginał (ang.) |
| Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones. |
businesswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-02-07 18:30:00 |
Czytaj oryginał (ang.) |
| Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-05 12:21:37 |
Czytaj oryginał (ang.) |
| Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know |
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales. |
zacks.com |
2025-02-04 14:50:35 |
Czytaj oryginał (ang.) |
| Incyte (INCY) Earnings Expected to Grow: Should You Buy? |
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-03 13:00:35 |
Czytaj oryginał (ang.) |
| Incyte Gains 15.3% in a Year: Is There Room for Further Growth? |
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels. |
zacks.com |
2025-01-20 17:36:17 |
Czytaj oryginał (ang.) |
| Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes |
– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups – WILMINGTON, Del. and WALTHAM, Mass. |
prnewswire.com |
2025-01-15 19:34:00 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding to Your Portfolio in 2025 |
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector. |
zacks.com |
2025-01-14 13:06:12 |
Czytaj oryginał (ang.) |
| Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 |
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. |
seekingalpha.com |
2025-01-13 20:10:02 |
Czytaj oryginał (ang.) |
| Has Incyte (INCY) Outpaced Other Medical Stocks This Year? |
Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year. |
zacks.com |
2025-01-13 12:46:35 |
Czytaj oryginał (ang.) |
| Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference. |
businesswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| EXEL vs. INCY: Which Stock Should Value Investors Buy Now? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-25 14:41:24 |
Czytaj oryginał (ang.) |
| Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY |
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-19 09:25:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY |
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-18 09:30:00 |
Czytaj oryginał (ang.) |
| Incyte to Present at Upcoming Investor Conference |
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discov. |
businesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-17 09:25:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY |
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-16 09:25:00 |
Czytaj oryginał (ang.) |
| Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-13 09:30:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of Incyte Corporation Shareholders. Contact Levi & Korsinsky to Discuss your INCY Losses |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-12 09:25:00 |
Czytaj oryginał (ang.) |
| Biotech Roundup: 3 Stocks to Watch |
Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F. |
schaeffersresearch.com |
2024-12-11 17:35:14 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY) |
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-11 09:25:00 |
Czytaj oryginał (ang.) |
| Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma. |
businesswire.com |
2024-12-10 12:30:00 |
Czytaj oryginał (ang.) |
| INCY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Incyte Corporation |
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-10 09:25:00 |
Czytaj oryginał (ang.) |
| Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals |
INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints. |
zacks.com |
2024-12-09 16:15:17 |
Czytaj oryginał (ang.) |
| EXEL or INCY: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-09 14:46:25 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY |
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-09 09:25:00 |
Czytaj oryginał (ang.) |
| Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC. |
businesswire.com |
2024-12-07 09:30:00 |
Czytaj oryginał (ang.) |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-12-06 18:30:00 |
Czytaj oryginał (ang.) |
| ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-06 09:25:00 |
Czytaj oryginał (ang.) |
| INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-05 09:30:00 |
Czytaj oryginał (ang.) |
| Incyte Corporation Being Investigated on Behalf of Incyte Corporation Investors. Contact Levi & Korsinsky For Details. |
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings. |
accesswire.com |
2024-12-04 09:30:00 |
Czytaj oryginał (ang.) |